Abstract
Abstract
Background
Trans women are at increased risk for HIV infection yet are less likely to use pre-exposure prophylaxis (PrEP) medication as a preventive measure. PrEP messaging and marketing has focused on men who have sex with men (MSM) or included trans women as a subset of MSM, ignoring the potential barriers to PrEP use unique to trans women. Little is known about how this group conceptualizes PrEP, what knowledge gaps still exist, and how trans women believe PrEP should be communicated to increase use.
Methods
This qualitative study conducted focus groups (n = 5) in Philadelphia and Sacramento with trans women to assess these issues.
Results
Twelve sub-themes were found related to five main domains, including PrEP knowledge, benefits, barriers, community-related considerations, and messaging/marketing. Findings indicate that knowledge of PrEP is still low and beliefs about PrEP’s effects on hormone use persist. Most importantly, participants voiced a demand for culturally appropriate trans-specific messages in HIV prevention interventions and communication.
Conclusions
Without acknowledging specific barriers to PrEP uptake among transgender women separate from those of MSM and incorporating gender affirmation into PrEP education, simply knowing PrEP is available may not motivate trans women to use PrEP. This has important implications for future efforts to communicate about PrEP with trans women.
Funder
National Institute of Mental Health
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference44 articles.
1. Baral SD, Poteat T, Stromdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(2):214–22. https://doi.org/10.1016/S1473-3099(12)70315-8.
2. Becasen JS, Denard CL, Mullins MM, Higa DH, Sipe TA. Estimating the prevalence of HIV and sexual behaviors among the US transgender population: a systematic review and meta-analysis, 2006-2017. Am J Public Health. 2019;1:e1–8. https://doi.org/10.2105/AJPH.2018.304727.
3. Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2010–2016. HIV Surveill Suppl Rep. 2019;23(1) http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed 23 Mar 2021.
4. Clark H, Babu AS, Wiewel EW, Opoku J, Crepaz N. Diagnosed HIV infection in transgender adults and adolescents: results from the national HIV surveillance system, 2009-2014. AIDS Behav. 2017;21:2774–83. https://doi.org/10.1007/s10461-016-1656-7.
5. Centers for Disease Control and Prevention. CDC-funded HIV testing: United States, Puerto Rico, and the U.S. Virgin Islands, 2014. https://www.cdc.gov/hiv/pdf/library/reports/cdc-hiv-funded-testing-us-puerto-rico-2014.pdf. Accessed 23 Mar 2021.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献